Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says

The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA.,…

Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says

A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at…

Japan stocks rebound to lead gains in Asia as traders assess U.S. inflation data, await BOJ meeting

Japan’s Mount Fuji seen in the Tokyo’s horizon on January 1, 2011. Kazuhiro Nogi | Afp…

European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai

European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another…

Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

A test tube is seen in front of displayed Biogen logo in this illustration taken on,…

These health-care companies see opportunity ahead from Alzheimer’s drug approval

As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs, blood…

Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know

The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January…

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

The Food and Drug Administration on Thursday fully approved the Alzheimer’s treatment Leqembi, a pivotal decision…

Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024

Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan…

Newseum Global